A guide to care questions / Claims to question

Which claims deserve a pause?

Check a claim before letting it set the pace. A confident answer can still leave the main question open.

Claims and shortcuts to question

FDA’s TB-500 review found no published human study supporting claims about healing injuries.

Thymosin beta-4 is the longer protein made by the body; evidence about it does not show what TB-500 does.

Ask for the study title and the exact substance it tested.

In warning letters reviewed in September 2026, FDA said sellers’ websites showed that their products were meant for people to use.

FDA said a label claiming research use did not change that finding or make those unapproved drug sales legal.

Treat the label and the claimed effect as separate things to question.

FDA registration and a National Drug Code did not establish product approval under the September 2026 rules.

Ask what the claimed stamp or code actually proves.

Under the guidance medical boards adopted in May 2026, prescribing from a patient’s menu choice alone falls short of the care standard.

The guidance adds that patients need a chance to put further questions to their clinician.

Ask who will assess the problem, how questions can be raised and what happens if the proposed treatment is declined.